28 0
Fundamentally a STRONG company and it had recent news for its upmove

Dr Reddy's Laboratories has expanded strategic collaboration with Amgen , one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis. Under the terms of the collaboration, the company will commercialise XGEVA'(denosumab), Vectibix' (panitumumab) and Prolia (donosumab) in India.

The BSE group 'A' stock of face value Rs . 5 has touched a 52 week high of Rs . 4382.95 on 20-Oct-2015 and a 52 week low of Rs . 2750.00 on 21-Jan-2016.

The promoters holding in the company stood at 26.37%, while institutions and non-institutions held 41.16% and 15.64% respectively.

Dr . Reddy’s Laboratories has been listed as an Index component of the Dow Jones Sustainability Indices (DJSI) 2016 in the Pharmaceuticals, Biotechnology & Life Sciences Industry Group. The pharma major has been recognized for its corporate sustainability leadership and is the only pharmaceutical company on the Index of Emerging Markets.
The listing was based on 22 criterion, with Dr . Reddy’s receiving high scores for Product Quality and Recall Management, Codes of Business Conduct, Environmental Reporting, Corporate Citizenship and Philanthropy.
ZH 繁體中文
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
AR العربية
HE עברית
首頁 股票篩選器 外匯篩選器 加密貨幣篩選器 全球財經日曆 如何運作 圖表功能 網站規則 版主 網站 & 經紀商解決方案 小工具 圖表庫 功能請求 部落格 & 新聞 常見問題 幫助 & 維基 推特
個人資料 個人資料設定 帳戶和帳單 我的客服工單 聯絡客服 發表的想法 粉絲 正在關注 私人訊息 在線聊天 登出